Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Titan Pharma (TTNP) Reports Q2 Loss of $0.11, Revenues Beat
November 14, 2018 4:21 PM ESTTitan Pharma (NASDAQ: TTNP) reported Q2 EPS of ($0.11), versus ($0.20) reported last year. Revenue for the quarter came in at $1.6 million versus the consensus estimate of $100 thousand.
"In order to maximize the significant market opportunity represented by our lead product, Probuphine®, we were... More
